January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria. Review of the applications is expected to by completed in Q4 2025, ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Most of the time, psoriasis is the first symptom of psoriatic arthritis. It causes silvery-white skin lesions called plaques, which may appear on your scalp, elbows, knees, and lower back. Eventually, ...

A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse cardiovascular and venous thromboembolic events compared with those treated ...

While Tremfya is seen as a follow-up to Stelara psoriatic arthritis is becoming a highly crowded market, where Novartis’ IL-17 inhibitor Cosentyx (secukinumab) is becoming well established.

Stelara, which is also an injectable treatment for autoimmune conditions but not for rheumatoid arthritis, is also a blockbuster drug although its peak annual sales have been about half the size of ...

There's no cure for psoriatic arthritis. Treatment is aimed at controlling symptoms and preventing joint damage. The medicines used to treat psoriatic arthritis include: non-steroidal anti ...

While speaking at the conference, J&J’s CEO, Joaquin Duato, indicated the company’s willingness to protect Stelara, its branded anti-interleukin (IL)-12/23 biologic, against sales erosion from ...